Search - tctmd.com

Displaying 1 - 20 of 92

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

Talking Sex: CVD Patients Want to Hear More From Clinicians

News Conference News AHA 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

November 20, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

November 18, 2024

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

News Conference News AHA 2024

Email Nudges Spur Patients With a History of Acute MI to Get Flu Shots

November 17, 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Michael O'Riordan

November 15, 2024

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

November 17, 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

November 15, 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

November 14, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

News Conference News AHA 2023

Intensive BP Reduction Lowers Dementia Risk in China Rural Hypertension Study

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.